Rondo Therapeutics emerges from stealth with $67M Series A financing

Rondo Therapeutics, a new immune-oncology-focused biotech based in San Francisco, USA, today emerged from stealth mode with its announcement of an oversubscribed $67 million Series A round of funding.

Proceeds will support the continued development of Rondo’s pre-clinical pipeline as the company advances its lead bispecific antibody candidates toward initial Phase I clinical studies. The financing was co-led by Red Tree Venture Capital and Canaan Partners, and included significant investment from Johnson & Johnson Innovation – JJDC. Additional investors included Novo Holdings and SV Health Investors.

“We are thrilled with the strong investment syndicate we have brought together. Each investment partner brings a unique perspective along with deep experience in therapeutics and a true understanding of what it takes to develop first- and best-in-class drugs. As repeat entrepreneurs, we know the value of having highly engaged investors that share our vision for building Rondo,” said Shelley Force Aldred, co-founder and chief executive of Rondo Therapeutics.